BMS' Abilify Gains Third Pediatric Indication: Autism-Related Irritability
This article was originally published in The Pink Sheet Daily
Executive Summary
New claim puts the atypical antipsychotic on par with J&J's Risperdal.
You may also be interested in...
FDA Autism Meeting: Will It Stray From Symptoms And Treatments To Causation?
US agency may face challenge of keeping May 4 meeting on patient-focused drug development focused on autism disease burden and current therapeutic approaches rather than vaccine safety.
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Otsuka Holdings Co., the parent of Japanese drug maker Otsuka Pharmaceutical Co. Ltd., has scheduled its long-planned initial public offering for December 15
Otsuka Plans $2.8 Billion IPO To Feed Global Expansion
Still fueled by growth of the anti-psychotic Abilify, the Japanese pharma's parent company plans to list on the Tokyo Stock Exchange on December 15.